<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The molecular bases of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) are not fully understood </plain></SENT>
<SENT sid="1" pm="."><plain>Trimethylated <z:chebi fb="0" ids="15358">histone</z:chebi> 4 lysine 3 (H3K4me3) is present in promoters of actively transcribed genes and has been shown to be involved in hematopoietic differentiation </plain></SENT>
<SENT sid="2" pm="."><plain>We performed a genome-wide H3K4me3 CHIP-Seq analysis of primary <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> bone marrow (BM) CD34+ cells </plain></SENT>
<SENT sid="3" pm="."><plain>This resulted in the identification of 36 genes marked by distinct higher levels of promoter H3K4me3 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>A majority of these genes are involved in NF-kB activation and innate immunity signaling </plain></SENT>
<SENT sid="5" pm="."><plain>We then analyzed expression of <z:chebi fb="0" ids="15358">histone</z:chebi> demethylases and observed significant overexpression of the JmjC-domain <z:chebi fb="0" ids="15358">histone</z:chebi> demethylase JMJD3 (KDM6b) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> CD34+ cells </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, we demonstrated that JMJD3 has a positive effect on transcription of multiple CHIP-Seq identified genes involved in NF-kB activation </plain></SENT>
<SENT sid="7" pm="."><plain>Inhibition of JMJD3 using shRNA in primary BM <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> CD34+ cells resulted in an increased number of erythroid colonies in samples isolated from patients with lower-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Taken together, these data indicate the deregulation of H3K4me3 and associated abnormal activation of innate immunity signals play a role in the pathogenesis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and that targeting these signals may have potential therapeutic value in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>.<z:hpo ids='HP_0001909'>Leukemia</z:hpo> accepted article preview online, 29 March 2013; doi:10.1038/leu.2013.91 </plain></SENT>
</text></document>